Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    8315120 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Clinical Trials to Reduce the Risk of Antimicrobial Resistance
Condition: Bacterial Pneumonia
Interventions: Drug: IV meropenem;   Drug: I.V. Meropenem;   Drug: Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h;   Drug: Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.;   Device: tobramycin nebulization

Indicates status has not been verified in more than two years